Body Fluid Collection and Diagnostics Market Size & Growth Forecast 2027–2036, By Segments (Product, Application, Sample, Technology), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Body Fluid Collection and Diagnostics Market size stood at USD 38.6 billion in 2026 and is predicted to grow at a 6.53% CAGR from 2027 to 2036, reaching USD 72.66 billion by 2036. The industry revenue for 2027 is assessed at USD 40.72 billion.
Get more details on this report
Request Free Sample ReportBody Fluid Collection and Diagnostics Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 47.12% of the market in 2026, driven by advanced diagnostic infrastructure, widespread fluid-based testing, and strong adoption of upgraded collection systems that improve workflow efficiency.
- Asia Pacific is expected to expand at a 7.57% CAGR as healthcare systems strengthen laboratory networks, increase diagnostic testing capacity, and invest in reliable sample collection technologies.
Segment Momentum
- Kits & Consumables hold 65.71% share due to repeat-use requirements in every diagnostic cycle, making them essential for routine sample collection, preparation, and scalable clinical and laboratory workflows.
- Therapeutic Decision Making is growing fastest as clinicians increasingly rely on diagnostic outputs to directly guide treatment selection, making body fluid analysis central to active care decisions beyond routine monitoring.
Market Expansion Drivers
- Growing focus on early disease detection increasing adoption of fluid-based diagnostic testing.
- Advancements in AI-integrated in-vitro diagnostics improving testing speed and diagnostic accuracy.
- Rising prevalence of blood disorders and cancer boosting demand for biomarker-based diagnostics.
Leading Market Participants
- Key players in the body fluid collection and diagnostics market include Thermo Fisher Scientific Inc. (United States), Bio-Rad Laboratories, Inc. (United States), Roche Holding AG (Switzerland), Qiagen N.V. (Germany), Illumina, Inc. (United States), Laboratory Corporation of America Holdings (United States), Becton, Dickinson and Company (United States), Quest Diagnostics Incorporated (United States), Abbott Laboratories (United States), Johnson & Johnson (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 38.6 billion
- 2027 Estimated Market Size: USD 40.72 billion.
- Projected Market Size: USD 72.66 billion by 2036
- Growth Forecast: 6.53% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Kits & Consumables (Product) | Diagnostics & Monitoring (Application) | Blood (Sample) | Polymerase Chain Reaction (PCR) (Technology)
- Emerging Opportunity Segment: Kits & Consumables (Product) | Therapeutic Decision Making (Application) | Urine (Sample) | Next Generation Sequencing (Technology)
Market Growth Drivers and Industry Trends
Growing focus on early disease detection increasing adoption of fluid-based diagnostic testing
The body fluid collection and diagnostics market is being supported by increasing emphasis on identifying diseases at earlier stages, when timely diagnosis can enable more appropriate clinical intervention and patient management. Blood, urine, saliva, and other biological fluids provide accessible sources for detecting disease-associated markers, metabolic abnormalities, infections, and other physiological changes without necessarily requiring invasive tissue sampling. Improvements in collection methods and diagnostic workflows are making fluid-based testing more practical across clinical settings, preventive screening programs, and routine assessments. The expanding focus on proactive healthcare and earlier identification of pathological changes is encouraging greater utilization of reliable fluid collection and diagnostic procedures.
Advancements in AI-integrated in-vitro diagnostics improving testing speed and diagnostic accuracy
Advancements in artificial intelligence are creating new opportunities for the body fluid collection and diagnostics market by enabling diagnostic platforms to process complex biological information more efficiently and support more consistent interpretation of test results. AI-integrated in-vitro diagnostic systems can assist with pattern recognition, signal analysis, anomaly identification, and interpretation of multiple biomarkers, helping laboratories manage increasingly sophisticated testing workflows. When combined with improved sample handling and automated processing technologies, these capabilities can shorten diagnostic workflows while reducing the potential for manual interpretation errors. Increasing incorporation of intelligent analytical functions into laboratory diagnostics is strengthening the value of advanced fluid-based testing systems.
Rising prevalence of blood disorders and cancer boosting demand for biomarker-based diagnostics
Rising prevalence of blood disorders and cancer is increasing demand in the body fluid collection and diagnostics market as clinicians rely on biological samples to identify and monitor disease-associated biomarkers. Fluid-based testing can provide information relevant to disease screening, diagnosis, treatment selection, and ongoing monitoring, particularly as laboratory medicine increasingly incorporates molecular and biomarker-based approaches. Advances in analytical techniques are enabling the detection of increasingly specific biological indicators in collected samples, supporting more detailed assessment of disease characteristics and patient responses. The expanding clinical role of biomarkers is consequently increasing requirements for dependable sample collection, preparation, and diagnostic workflows.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Growing focus on early disease detection increasing adoption of fluid-based diagnostic testing | 2.30% | High | North America, Europe | High | Near Term |
| Advancements in AI-integrated in-vitro diagnostics improving testing speed and diagnostic accuracy | 2.00% | Moderate | Asia Pacific, North America | High | Mid Term |
| Rising prevalence of blood disorders and cancer boosting demand for biomarker-based diagnostics | 1.70% | High | North America, Asia Pacific | High | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America held the largest share of the body fluid collection and diagnostics market, representing 47.12% share in 2026. The region benefits from well-developed diagnostic infrastructure, widespread adoption of laboratory technologies, and strong demand for accurate and efficient specimen collection and testing across healthcare settings. Increasing emphasis on timely diagnosis, laboratory workflow efficiency, and infection control supports the use of standardized collection and diagnostic solutions. Established healthcare systems and continued technological advancement further strengthen regional demand.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is emerging as the fastest-growing region, driven by expanding diagnostic capacity, improving healthcare access, and increasing demand for laboratory-based disease detection. Investments in healthcare infrastructure are enabling broader deployment of modern diagnostic equipment and specimen-management systems, while growing awareness of preventive healthcare is encouraging greater use of diagnostic testing. The expansion of hospitals, laboratories, and decentralized healthcare services is also widening the application base for body fluid collection and diagnostic technologies.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Laboratory Quality StandardsGermany emphasizes body fluid collection solutions that support standardized laboratory practices and high analytical accuracy. Healthcare institutions prioritize products that maintain sample integrity and integrate smoothly with automated diagnostic workflows.
France 🇫🇷
Clinical Testing ReliabilityFrance prioritizes body fluid collection products that support dependable diagnostic performance across hospitals and clinical laboratories. Healthcare providers seek standardized collection methods that improve operational consistency and reduce pre-analytical errors.
Italy 🇮🇹
Routine Diagnostics ExpansionItaly continues to expand the use of body fluid collection devices across routine diagnostics and specialized laboratory services. The market favors practical solutions that simplify sample handling while maintaining reliable diagnostic performance.
Japan 🇯🇵
Precision Sample ManagementJapan focuses on body fluid collection technologies that improve specimen quality and reduce handling variability. Diagnostic laboratories and healthcare providers value dependable collection systems that complement advanced analytical platforms.
South Korea 🇰🇷
Digital Diagnostics SupportSouth Korea is strengthening body fluid collection and diagnostics through investments in modern laboratory infrastructure and digital healthcare. Demand favors collection devices that improve traceability, efficiency, and compatibility with automated diagnostic systems.
United States 🇺🇸
Integrated Diagnostic TestingThe U.S. body fluid collection and diagnostics market is driven by demand for accurate, efficient specimen collection across hospitals, laboratories, and outpatient settings. Providers increasingly prefer integrated collection systems that enhance workflow efficiency and diagnostic reliability.
Segment Leadership and Growth Trends
Body Fluid Collection and Diagnostics Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Kits & Consumables (Largest & Fastest-Growing Segment)
Kits & consumables led the body fluid collection and diagnostics market with a 65.71% share in 2026, while also representing the fastest-growing product segment. Their strong position reflects the routine need for collection containers, preparation materials, testing components, and other disposable products across diagnostic workflows. These products support standardized sample handling and help laboratories and healthcare providers maintain efficient testing procedures while minimizing contamination risks. Their recurring use across a broad range of diagnostic applications, combined with increasing emphasis on convenient and ready-to-use testing formats, continues to strengthen demand. The growing adoption of decentralized and laboratory-based diagnostics further supports the role of kits and consumables as essential components of body fluid testing workflows.
Application Segment Analysis: Diagnostics & Monitoring (Largest Segment) vs Therapeutic Decision Making (Fastest-Growing Segment)
Diagnostics & monitoring accounted for the largest share of the body fluid collection and diagnostics market, reaching 44.24% in 2026, driven by the fundamental role of body fluid analysis in identifying diseases, assessing patient conditions, and tracking clinical changes. Blood, urine, saliva, and other biological samples provide important information for routine screening and ongoing disease assessment, making diagnostic collection and testing an integral part of healthcare delivery. Greater emphasis on early detection, personalized clinical assessment, and continuous patient monitoring is supporting sustained utilization across hospitals, laboratories, and other healthcare settings.
Therapeutic decision making is emerging as the fastest-growing application as healthcare providers increasingly use diagnostic information to guide treatment selection and refine patient management. Analysis of body fluids can provide clinically relevant insights that help physicians evaluate disease characteristics, treatment response, and potential therapeutic options. The expanding use of data-driven and personalized care approaches is increasing the importance of diagnostic results beyond initial disease identification. As clinical workflows become more closely connected with treatment planning, body fluid diagnostics are gaining a stronger role in supporting targeted and informed therapeutic decisions.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Tests/Services, Kits & Consumables, Instruments | Kits & Consumables | Kits & Consumables |
| Application | Diagnostics & Monitoring, Therapeutic Decision Making, Prognostics & Screening | Diagnostics & Monitoring | Therapeutic Decision Making |
| Sample | Blood, Saliva, Urine, Cerebrospinal Fluid | Blood | Urine |
| Technology | Next Generation Sequencing, Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence in Situ Hybridization (FISH), Others | Polymerase Chain Reaction (PCR) | Next Generation Sequencing |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Top players in the body fluid collection and diagnostics market:
1. Thermo Fisher Scientific Inc. (United States)
2. Bio-Rad Laboratories Inc. (United States)
3. Roche Holding AG (Switzerland)
4. Qiagen N.V. (Germany)
5. Illumina Inc. (United States)
6. Laboratory Corporation of America Holdings (United States)
7. Becton Dickinson and Company (United States)
8. Quest Diagnostics Incorporated (United States)
9. Abbott Laboratories (United States)
10. Johnson & Johnson (United States)
The body fluid collection and diagnostics market is expanding through advancements in automated sampling systems, rapid diagnostic technologies, and contamination-reduction solutions. Increasing focus on accuracy, workflow efficiency, and minimally invasive testing procedures is driving innovation across diagnostic applications. Demand for early disease detection and laboratory automation is further strengthening market growth.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Roche Holding AG (Switzerland) | |||||||
| Qiagen N.V. (Germany) | |||||||
| Illumina Inc. (United States) | |||||||
| Laboratory Corporation of America Holdings (United States) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| Quest Diagnostics Incorporated (United States) | |||||||
| Abbott Laboratories (United States) | |||||||
| Johnson & Johnson (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Guardant Health | May-25 | Guardant Health expanded its Guardant360 platform with new smart liquid-biopsy applications, enabling comprehensive molecular profiling, cancer subtyping, and HLA genotyping from a single blood draw. This technical integration enhances the utility of liquid biopsy for precision oncology, improving the speed and depth of diagnostic data available for personalized cancer treatment and therapeutic monitoring. |
| Becton Dickinson | Mar-25 | Becton Dickinson released study data validating that its MiniDraw capillary collection system provides diagnostic accuracy equivalent to traditional venous sampling. This validation supports the adoption of less-invasive collection methods, potentially increasing patient compliance with routine testing and streamlining workflow efficiency in decentralized diagnostic and primary care environments. |
| Labcorp | Feb-25 | Labcorp launched "Plasma Complete," a high-sensitivity liquid biopsy test featuring 521-gene coverage and 0.1% variant sensitivity. By providing a deeper genomic profile of circulating tumor DNA, this diagnostic tool enhances the company’s precision oncology portfolio, enabling more accurate detection of low-frequency mutations and supporting clinicians in making informed treatment decisions for cancer patients. |
| Danaher | Jan-25 | Danaher established a strategic investment partnership with Innovaccer to integrate AI-driven diagnostic insights directly into unified patient health records. This initiative aims to bridge the gap between diagnostic results and clinical decision-making, providing a scalable digital infrastructure that enhances the diagnostic value chain and promotes more coordinated patient care across hospital networks. |
| Guardant Health | Sep-24 | Guardant Health entered a partnership with Policlinico Gemelli to establish an in-house liquid biopsy service in Italy. This collaboration aims to localize advanced diagnostic testing, reducing turnaround times for molecular results and expanding patient access to cutting-edge cancer detection technologies within the European clinical research and oncology care landscape. |
| Guardant Health | Jul-24 | The FDA approved the Shield blood test as a primary screening method for colorectal cancer, making it the first blood-based diagnostic cleared for this indication. This regulatory approval facilitates Medicare reimbursement and provides a non-invasive screening alternative for average-risk individuals, significantly broadening the market for convenient, accessible colorectal cancer early detection and prevention services. |
| Spectrum Solutions | Mar-24 | Spectrum Solutions introduced a non-invasive, saliva-based diagnostic testing solution designed for faster health assessments. This development leverages saliva as a reliable bio-specimen for broad-condition detection, marking a strategic shift toward patient-friendly, low-complexity diagnostic tools that reduce sample collection barriers and enhance the clinical feasibility of routine health monitoring and longitudinal wellness tracking. |
| Siemens Healthineers | May-23 | Siemens Healthineers launched the Atellica HEMA 580 and 570 hematology analyzers, incorporating multi-analyzer automation connectivity and intuitive user interfaces. These next-generation systems are designed to eliminate workflow bottlenecks in clinical laboratories, supporting high-throughput diagnostic environments and accelerating result turnaround times for essential hematological assessments. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Body Fluid Collection and Diagnostics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Disease Indication | Infectious Diseases, Oncology, Neurological Disorders, Cardiovascular & Metabolic Disorders, Other Clinical Indications |
| Distribution Channel | Direct Sales, Distributor/Dealer Networks, Online & E-Commerce Channels |
| Reimbursement Status | Reimbursed Testing, Partially Reimbursed Testing, Non-Reimbursed Testing |
Body Fluid Collection and Diagnostics Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Diagnostic Testing Workflow Optimization Assessment |
|
| Point-of-Care Adoption Opportunity Analysis |
|
| Specimen Collection Supply Chain Resilience Assessment |
|
Need a different cut of the data?
Request Custom ResearchHow much revenue does the body fluid collection and diagnostics market generate?
What are the growth projections for the body fluid collection and diagnostics industry?
How is the shift toward early disease detection impacting demand in the body fluid collection and diagnostics market?
What is the impact of AI integration on in-vitro diagnostics workflows in this market?
Why do kits and consumables lead the body fluid collection and diagnostics market?
Why is therapeutic decision making the fastest-growing application in this market?
What factors support North America's leadership in the body fluid collection and diagnostics market?
Why is Asia Pacific the fastest-growing region in the body fluid collection and diagnostics market?
What are the prominent companies operating in the body fluid collection and diagnostics landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization